MedTrace Logo

Venous Thromboprophylaxis in Bariatric Surgery

NCT03218514 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2018-10-18

No results posted yet for this study

Summary

The main aim of this study is to compare the influence of total body-weight (TBW), lean body-weight (LBW), ideal body-weight (IBW) or Body Mass Index (BMI) on peak anti-Xa levels at steady-state in bariatric surgery (BS) morbidly obese patients receiving a fixed double dose of dalteparin (5000 IU subcutaneously, twice daily a day) for venous thromboembolism (VTE) prevention. Secondary aims of this study are to identify which body size descriptors (BSD) has the greatest impact and could further be explored for an adjusted low molecular weight heparin (LMWH) dosing algorithm for achieving optimal VTE prevention in BS severely obese patients.

Conditions

Interventions

DRUG

Dalteparin

Sponsors & Collaborators

  • Assistance Publique Hopitaux De Marseille

    collaborator OTHER

  • Groupe Hospitalier Pitie-Salpetriere

    lead OTHER

Principal Investigators

  • Benedicte Gaborit · Inserm U1062, Inra U1260, Aix Marseille Université, Faculté de Médecine, Assistance Publique - Hôpitaux de Marseille

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-03-31
Completion
2017-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03218514 on ClinicalTrials.gov